ELTX
Elicio Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$198.65M
P/E Ratio
—
EPS
$-2.58
Beta
1.88
52W High
$14.93
52W Low
$4.85
50-Day MA
$11.27
200-Day MA
$9.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc. (ELTX) is an innovative clinical-stage biotechnology firm at the forefront of developing transformative immunotherapy solutions for cancer treatment. The company's proprietary Amphiphilic TLR9 Agonist, Eli-002, is designed to stimulate strong immune responses against various cancer types, aiming to significantly improve treatment outcomes for patients. With a strategic emphasis on personalized cancer vaccines and cutting-edge immunotherapeutic strategies, Elicio is well-positioned to address substantial unmet medical needs within oncology, actively advancing its clinical trials to redefine cancer care.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-37.51M |
| Operating Margin | 0.00% |
| Return on Equity | -60013.00% |
| Return on Assets | -87.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.09 |
| Price-to-Book | 120.62 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $18.70M |
| Float | $12.71M |
| % Insiders | 30.37% |
| % Institutions | 13.99% |
Historical Volatility
HV 10-Day
75.24%
HV 20-Day
74.47%
HV 30-Day
72.64%
HV 60-Day
88.93%
HV Rank
46.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($17.50 target)
2
BuyData last updated: 5/1/2026